Vertex Trikafta Approved As First Triple Combo For Cystic Fibrosis With $311,503 Price Tag
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.
You may also be interested in...
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
Keeping Track: Vertex’ Trikafta Speeds To US Approval; New Indications For AZ’s Farxiga, J&J’s Stelara, GSK’s Zejula
The latest drug development news and highlights from our US FDA Performance Trackers.
Vertex has struck a reimbursement deal in Spain for Orkambi and hopes that it will also make progress in England where a new proposal has been made by the company.